Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
The Pharma Data
JANUARY 31, 2021
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR ® technology and structure-based drug design platform capabilities. . TOKYO and CAMBRIDGE, England , Feb. ” About Sosei Heptares.
52 
Let's personalize your content